Published in Proc Natl Acad Sci U S A on July 01, 1986
Epidemiological Aspects and World Distribution of HTLV-1 Infection. Front Microbiol (2012) 3.03
Antenatal survey for the seroprevalence of HTLV-1 infections in the West Midlands, England. Epidemiol Infect (1993) 1.65
Screening for prolonged incubation of HTLV-I infection in British and Jamaican relatives of British patients with tropical spastic paraparesis. BMJ (1990) 1.45
Sexual transmission of human T-cell leukemia virus type I associated with the presence of anti-Tax antibody. Proc Natl Acad Sci U S A (1991) 0.90
Prevalence of HTLV types I and II among drug users in King County, Washington. West J Med (1994) 0.88
Infection with the human T-lymphotropic virus type I. A review for clinicians. West J Med (1989) 0.85
Familial transmission of human T-cell lymphotrophic virus: silent dissemination of an emerging but neglected infection. PLoS Negl Trop Dis (2013) 0.78
High prevalence of HTLV-1 infection among Japanese immigrants in non-endemic area of Brazil. PLoS Negl Trop Dis (2015) 0.77
Prevalence of human T-lymphotropic virus in civilian applicants for the United States Armed Forces. Am J Public Health (1992) 0.77
Infection with human T-lymphotropic virus types-1 and -2 (HTLV-1 and -2): Implications for blood transfusion safety. Transfus Clin Biol (2016) 0.77
Prevalence of antibody to human T-cell lymphotropic virus type I/II in people of Caribbean origin in Toronto. CMAJ (1992) 0.76
A serosurvey for HTLV-I among high-risk populations and normal adults in Egypt. Epidemiol Infect (1991) 0.76
Human T-lymphotropic virus type I (HTLV-I) and tropical spastic paraparesis or HTLV-I-associated myelopathy in Hawaii. West J Med (1990) 0.76
Human T-lymphotropic virus type I seroprevalence among Japanese Americans. West J Med (1993) 0.75
HTLV-III in symptom-free seronegative persons. Lancet (1984) 2.71
The human type-C retrovirus, HTLV, in Blacks from the Caribbean region, and relationship to adult T-cell leukemia/lymphoma. Int J Cancer (1982) 2.71
Natural antibodies to human retrovirus HTLV in a cluster of Japanese patients with adult T cell leukemia. Science (1982) 2.62
Antibodies to adult T-cell leukemia-virus-associated antigen (ATLA) in sera from patients with ATL and controls in Japan: a nation-wide sero-epidemiologic study. Int J Cancer (1982) 2.39
Epidemiology of human T-cell leukemia/lymphoma virus. J Infect Dis (1983) 2.26
Ascertainment of men of Japanese ancestry in Hawaii through World War II Selective Service registration. J Chronic Dis (1970) 2.17
Mother-to-child transmission of human T-cell leukemia virus type-I. Jpn J Cancer Res (1985) 1.53
Seroepidemiologic studies of human T-cell leukemia/lymphoma virus type I in Jamaica. Int J Cancer (1985) 1.34
Prospective study of alcohol consumption and cancer. N Engl J Med (1984) 1.23
High incidence of HTLV antibody in carriers of Strongyloides stercoralis. Lancet (1984) 1.19
Oral transmission of human T-cell leukemia virus type-I into a common marmoset (Callithrix jacchus) as an experimental model for milk-borne transmission. Jpn J Cancer Res (1985) 1.12
Seroepidemiological studies on the effects of filarial parasites on infestation of adult T-cell leukemia virus in the Goto Islands, Japan. Gan (1983) 1.05
Type-I HTLV antibody in urban and rural Ghana, West Africa. Int J Cancer (1984) 1.02
Prevalence of possible adult T-cell leukemia virus-carriers among volunteer blood donors in Japan: a nation-wide study. Int J Cancer (1984) 1.01
Reactivation of latent feline leukaemia virus infection. Nature (1982) 1.00
Vertical transmission of adult T-cell leukaemia virus. Lancet (1983) 1.00
Human T-cell leukemia virus (HTLV) in the United Kingdom. Int J Cancer (1984) 0.92
Evidence for human T cell lymphoma-leukemia virus infection of family members of human T cell lymphoma-leukemia virus positive T cell leukemia-lymphoma patients. J Exp Med (1983) 0.92
Seroepidemiology of human T-lymphotropic retrovirus type I (HTLV-I) in residents of Niigata Prefecture, Japan. Comparative studies by indirect immunofluorescence microscopy and enzyme-linked immunosorbent assay. Int J Cancer (1985) 0.92
High incidence of human type-C retrovirus (HTLV) in family members of a HTLV-positive Japanese T-cell leukemia patient. Proc Natl Acad Sci U S A (1983) 0.91
Human T-cell leukemia-lymphoma virus type 1 and adult T-cell leukemia-lymphoma in Okinawa. Cancer Res (1985) 0.86
Human T-cell leukemia/lymphoma viruses: clinical and epidemiologic features. Curr Top Microbiol Immunol (1985) 0.81
Natural antibodies to human T-cell leukemia/lymphoma virus in healthy Venezuelan populations. Int J Cancer (1984) 0.80
[Clinical features of malignant lymphoma and adult T-cell leukemia in Kumamoto]. Rinsho Ketsueki (1983) 0.79
HTLV antibody positivity and incidence of adult T-cell leukaemia in Kochi prefecture, Japan. Lancet (1983) 0.79
HTLV and the propagation of Christianity in Nagasaki. Lancet (1984) 0.78
Selective in vitro growth of T lymphocytes from normal human bone marrows. Science (1976) 15.73
Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res (1995) 11.07
A cancer family syndrome in twenty-four kindreds. Cancer Res (1988) 6.39
HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope. Science (1986) 6.33
Quality of informed consent in cancer clinical trials: a cross-sectional survey. Lancet (2001) 6.07
Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood (1979) 6.01
Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J Virol (1988) 5.96
PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. J Clin Microbiol (1997) 5.76
A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science (1982) 5.30
HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature (1985) 5.10
Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science (1983) 4.72
Seroepidemiology of HTLV-III antibody in Danish homosexual men: prevalence, transmission, and disease outcome. Br Med J (Clin Res Ed) (1984) 4.39
Screening test for HTLV-III (AIDS agent) antibodies. Specificity, sensitivity, and applications. JAMA (1985) 4.26
Natural antibodies to the structural core protein (p24) of the human T-cell leukemia (lymphoma) retrovirus found in sera of leukemia patients in Japan. Proc Natl Acad Sci U S A (1982) 3.75
Adult T-cell lymphoma-leukaemia in Blacks from the West Indies. Lancet (1982) 3.67
Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA (1996) 3.50
Age at establishment of Helicobacter pylori infection and gastric carcinoma, gastric ulcer, and duodenal ulcer risk. Cancer Res (1995) 3.30
Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS. Science (1984) 3.20
Expression of the HTLV-III envelope gene by a recombinant vaccinia virus. Nature (1986) 3.19
Prevalence of antibodies to HTLV-I, -II, and -III in intravenous drug abusers from an AIDS endemic region. JAMA (1986) 3.05
Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene. Cell (1988) 2.91
Quality of informed consent: a new measure of understanding among research subjects. J Natl Cancer Inst (2001) 2.85
Female prostitutes: a risk group for infection with human T-cell lymphotropic virus type III. Lancet (1985) 2.84
The virus of Japanese adult T-cell leukaemia is a member of the human T-cell leukaemia virus group. Nature (1982) 2.75
Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J Infect Dis (1996) 2.74
HIV/HTLV gene nomenclature. Nature (1988) 2.72
The human type-C retrovirus, HTLV, in Blacks from the Caribbean region, and relationship to adult T-cell leukemia/lymphoma. Int J Cancer (1982) 2.71
Natural antibodies to human retrovirus HTLV in a cluster of Japanese patients with adult T cell leukemia. Science (1982) 2.62
Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc Natl Acad Sci U S A (1989) 2.62
Natural history of HIV-1 cell-free viremia. JAMA (1995) 2.58
Detection of the human T cell lymphoma virus p19 in cells of some patients with cutaneous T cell lymphoma and leukemia using a monoclonal antibody. J Exp Med (1981) 2.47
Further observations on the persistence of Treponema pallidum after treatment in rabbits and humans. Br J Vener Dis (1968) 2.37
Association of human T lymphotropic virus type III antibodies with sexual and other behaviors in a cohort of homosexual men from Boston with and without generalized lymphadenopathy. Am J Med (1986) 2.33
Characterization of the MexC-MexD-OprJ multidrug efflux system in DeltamexA-mexB-oprM mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1998) 2.29
Epidemiology of human T-cell leukemia/lymphoma virus. J Infect Dis (1983) 2.26
Cytoplasmic localization of the HTLV-III 3' orf protein in cultured T cells. Virology (1986) 2.25
Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I. Int J Cancer (1989) 2.24
Human papillomavirus infection and other risk factors for cervical neoplasia: a case-control study. Int J Cancer (1991) 2.19
Mathematical model of an adult human atrial cell: the role of K+ currents in repolarization. Circ Res (1998) 2.18
Serological analysis of cellular and viral DNA polymerases by an antiserum to DNA polymerase gamma of human lymphoblasts. Biochemistry (1977) 2.18
Mother-to-infant transmission of human immunodeficiency virus type 1: association with prematurity or low anti-gp120. Lancet (1989) 2.12
Neurologic manifestations of human immunodeficiency virus infection in children. Pediatrics (1986) 2.09
Statistical approach to evaluating the method of Morgan and Vryonis for enumerating Treponema pallidum. Appl Microbiol (1969) 2.07
Long-term seropositivity for human T-lymphotropic virus type III in homosexual men without the acquired immunodeficiency syndrome: development of immunologic and clinical abnormalities. A longitudinal study. Ann Intern Med (1986) 2.06
Endothelin, a novel vasoconstrictor peptide, as potent bronchoconstrictor. Eur J Pharmacol (1988) 2.06
Expression of alternatively spliced human T-lymphotropic virus type I pX mRNA in infected cell lines and in primary uncultured cells from patients with adult T-cell leukemia/lymphoma and healthy carriers. Proc Natl Acad Sci U S A (1992) 2.05
Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. J Virol (1987) 1.99
Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. J Virol (1998) 1.98
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol (2014) 1.97
Multiple sclerosis and human T-cell lymphotropic retroviruses. Nature (1985) 1.96
DNA polymerase gamma of human lymphoblasts. Biochemistry (1977) 1.94
Mortality among chemical workers exposed to benzene and other agents. Environ Res (1983) 1.94
Transactivation of interleukin 2 and its receptor induces immune activation in human T-cell lymphotropic virus type I-associated myelopathy: pathogenic implications and a rationale for immunotherapy. Proc Natl Acad Sci U S A (1990) 1.93
Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest (1996) 1.92
In vitro generation of an HTLV-III variant by neutralizing antibody. J Immunol (1986) 1.91
Clinical, pathologic, and immunologic features of human T-lymphotrophic virus type I-associated infective dermatitis in children. Arch Dermatol (1998) 1.90
Natural antibodies to the human T cell lymphoma virus in patients with cutaneous T cell lymphomas. J Exp Med (1981) 1.84
Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer (1997) 1.82
Evidence for heterosexual transmission and clinical manifestations of human immunodeficiency virus infection and related conditions in Lusaka, Zambia. Lancet (1986) 1.80
The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope. J Virol (1990) 1.76
Comparison of the VDRL slide, TPI, and FTA-ABS tests in experimental syphilis in rabbits. Br J Vener Dis (1967) 1.74
Complications of cardiac catheterization in the current era: a single-center experience. Catheter Cardiovasc Interv (2001) 1.72
Separation of Treponema pallidum from tissue substances by continuous-flow zonal centrifugation. Appl Microbiol (1972) 1.72
A human cardiopulmonary system model applied to the analysis of the Valsalva maneuver. Am J Physiol Heart Circ Physiol (2001) 1.71
Humoral immune response to the entire human immunodeficiency virus envelope glycoprotein made in insect cells. Proc Natl Acad Sci U S A (1987) 1.70
Human T-cell leukaemia/lymphoma virus-associated lymphoreticular neoplasia in Jamaica. Lancet (1983) 1.69
HTLV-III large envelope protein (gp120) suppresses PHA-induced lymphocyte blastogenesis. J Immunol (1987) 1.69
Tissue inhibitor of metalloproteinases-2 gene polymorphisms in chronic obstructive pulmonary disease. Eur Respir J (2001) 1.65
Familial testicular cancer and urogenital developmental anomalies. Cancer (1985) 1.64
HLA-DR is involved in the HIV-1 binding site on cells expressing MHC class II antigens. J Immunol (1988) 1.63
Signal transduction, pharmacological properties, and expression patterns of two rat metabotropic glutamate receptors, mGluR3 and mGluR4. J Neurosci (1993) 1.63
Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat Med (1997) 1.62
Population-based monitoring of an urban HIV/AIDS epidemic. Magnitude and trends in the District of Columbia. JAMA (1992) 1.62
Functional replacement of OprJ by OprM in the MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa. FEMS Microbiol Lett (1998) 1.61
Human T-lymphotropic virus type I (HTLV-I) seroprevalence in Jamaica. I. Demographic determinants. Am J Epidemiol (1991) 1.61
Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment. Proc Natl Acad Sci U S A (1992) 1.59
Clinical course of retrovirus-associated adult T-cell lymphoma in the United States. N Engl J Med (1983) 1.58
Sexual transmission of human T-lymphotropic virus type I (HTLV-I). Ann Intern Med (1989) 1.57
The effects of cigarette smoking on T cell subsets. A population-based survey of healthy caucasians. Am Rev Respir Dis (1989) 1.57
IgG heavy-chain (Gm) allotypes and immune response to insulin in insulin-requiring diabetes mellitus. N Engl J Med (1981) 1.57
A distinctive clade B HIV type 1 is heterosexually transmitted in Trinidad and Tobago. Proc Natl Acad Sci U S A (2000) 1.55
A model of the action potential and underlying membrane currents in a rabbit atrial cell. Am J Physiol (1996) 1.55
Effects of a urinary factor from women in early pregnancy on HIV-1, SIV and associated disease. Nat Med (1998) 1.55
Amyl nitrite may alter T lymphocytes in homosexual men. Lancet (1982) 1.54
Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation (2001) 1.54
Nerve crush injuries--a model for axonotmesis. Exp Neurol (1994) 1.54
Association of HTLV-III antibodies and cellular immune status of hemophiliacs. N Engl J Med (1984) 1.51
Prevention of restenosis after angioplasty in small coronary arteries with probucol. Circulation (1998) 1.51
Development and early natural history of HTLV-III antibodies in persons with hemophilia. JAMA (1985) 1.50
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol (2005) 1.50
IgG heavy chain allotypes (Gm) in autoimmune diseases. Clin Exp Immunol (1980) 1.46